Romidepsin – Uses, Dosage, Side Effects, Interaction Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T-cell lymphomas. Romidepsin is associated with a modest rate of minor serum enzyme elevations during therapy but has not been linked to cases of clinically apparent liver injury, although it has been reported to cause reactivation of hepatitis B. Romidepsin is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Istodax for the treatment of certain types of cancer. Romidepsin is also being studied as an investigational drug as part of a strategy to cure HIV infection. As an HIV investigational drug, romidepsin belongs to a group of drugs called latency-reversing agents. Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T-cell lymphomas. Romidepsin is associated with a modest rate of minor serum enzyme elevations during therapy but has not been linked to cases of clinically apparent liver injury, although it has been reported to cause reactivation of hepatitis B. Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Mechanism of action Romidepsin is a prodrug, where it becomes active once taken up into the cell. The active metabolite has a free thiol group, which interacts with zinc ions in the active site of class 1 and 2 HDAC enzymes, resulting in inhibition of its enzymatic activity. Certain tumors have over expressed HDACs and downregulated/mutated histone acetyltransferases. This imbalance of HDAC relative to histone acetyltransferase can lead to a decrease in regulatory genes, ensuing tumorigenesis. Inhibition of HDAC may restore normal gene expression in cancer cells and result in cell cycle arrest and apoptosis. Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor. Many HDAC inhibitors are potential treatments for cancer through the ability to epigenetically restore normal expression of tumor suppressor genes, which may result in cell cycle arrest, differentiation, and apoptosis.[rx] Indications Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Romidepsin is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.[rx] Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas. Romidepsin is a histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma. Treatment of peripheral T-cell lymphoma (PTCL), Treatment of peripheral T-cell lymphoma (nodal, other extranodal, and leukemic/disseminated). Romidepsin is used to treat T-cell lymphoma affecting the skin (cutaneous T-cell lymphoma). Romidepsin is given after at least one other cancer treatment did not work or has stopped working. Romidepsin may also be used for purposes not listed in this medication guide. Use in Cancer Romidepsin is approved to treat: Cutaneous T-cell lymphoma in adults who have already been treated with at least one other type of systemic therapy. Romidepsin is also being studied in the treatment of other types of cancer Contraindications a bad infection low amount of magnesium in the blood low amount of potassium in the blood anemia decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils a decreased number of lymphocytes in the blood prolonged QT interval on EKG abnormal heart rhythm abnormal EKG with QT changes from birth severe liver disease pregnancy a patient who is producing milk and breastfeeding chronic kidney disease stage 5 (failure) Dosage Strengths: 10 mg; 5 mg/mL Cutaneous T-cell Lymphoma 14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy. For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy. Peripheral T-cell Lymphoma 14 mg/m2 IV over 4 hours on days 1, 8, and 15 of a 28-day cycle; repeat cycle every 28 days provided patient continues to benefit and is tolerating therapy For the treatment of cutaneous T-cell Lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least 1 prior systemic therapy. Dose Adjustments NONHEMATOLOGIC TOXICITIES (EXCEPT ALOPECIA): Grade 2 or 3: Delay therapy until toxicity returns to Grade 1 or less or baseline; resume at 14 mg/m2. Grade 3 recurrence: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2. Grade 4: Delay therapy until toxicity returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2. Grade 3 or 4 recurrence after dose reduction: Discontinue therapy. HEMATOLOGIC TOXICITIES: Grade 3 or 4 neutropenia or thrombocytopenia: Delay therapy until specific cytopenia returns to absolute neutrophil count (ANC) of 1.5 x 10(9)/L or greater and/or platelet count is 75 x 10(9)/L or baseline; restart at 14 mg/m2. Grade 4 febrile (38.5C or greater) neutropenia or thrombocytopenia requiring platelet transfusion: Delay therapy until specific cytopenia returns to Grade 1 or less or baseline; permanently reduce dose to 10 mg/m2. Administration advice: Administer IV over a 4-hour period. Nausea and vomiting are commonly reported; consider antiemetic support Preparation, handling, and disposal should be handled in a manner consistent with safe procedures and handling for cytotoxic drugs. Reconstituted solution (5 mg/mL) is chemically stable for up to 8 hours at room temperature. Diluted solution is chemically stable for up to 24 hours at room temperature; however, administration as soon as possible following dilution is advised. Prolongation of PT and elevation of INR were observed in a patient receiving this drug concomitantly with warfarin. Monitor PT and INR more frequently in these patients. Strong CYP450 3A4 inhibitors increase concentrations of this drug. Monitor for toxicity related to increased exposure to this drug and follow the dose modifications for toxicity. Rifampin (a potent CYP450 3A4 inducer) increases the concentrations of this drug. Avoid coadministration of this drug with rifampin. The use of other potent CYP450 3A4 inducers should be avoided when possible. Monitoring: Perform ECG at baseline and periodically, especially in patients with a history of significant cardiovascular disease, those on concomitant QT interval prolonging drugs, or those receiving antiarrhythmic drugs. Verify normal serum potassium and magnesium levels prior to initiating treatment, and periodically during therapy, especially in higher risk patients. Monitor for thrombocytopenia, anemia, neutropenia and lymphopenia during therapy; modify treatment as necessary. Monitor patients with advanced stage disease and/or high tumor burden; institute precautions and treat as needed. Patient advice: Report nausea and vomiting to your healthcare provider. This drug can lower blood counts and lower resistance to infection; contact your healthcare provider immediately if you experience with signs of infection, significant fatigue, or bleeding. Side Effects The Most Common nausea vomiting diarrhea constipation stomach pain mouth sores headache changed sense of taste loss of appetite itching tiredness or weakness pale skin shortness of breath chest pain irregular heartbeat feeling dizzy or faint easy bruising or bleeding fever, cough, flu-like symptoms, muscle aches, burning on urination, worsening skin problems, and other signs of infection (may occur up to 30 days after your treatment) rash blistering or peeling skin swelling of the hands, feet, ankles, or lower legs More common Black, tarry stools bleeding gums blood in the urine or stools blurred vision bone pain chest pain chills confusion cough decreased urine output difficulty with breathing dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position drowsiness dry mouth fast or irregular heartbeat fever flushed, dry skin fruit-like breath odor headache hoarseness increased hunger increased thirst increased urination joint pain, stiffness, or swelling loss of appetite lower back or side pain muscle cramps in the hands, arms, feet, legs, or face muscle spasms or twitching nausea numbness or tingling in the hands, fingertips, feet, or lips painful or difficult urination pale skin pinpoint red spots on the skin seizures sore throat sores, ulcers, or white spots on the lips or in the mouth stomach cramps or pain sweating swelling of the face, ankles, feet, lower legs, or hands swollen glands tremor trouble breathing unexplained weight loss unusual bleeding or bruising unusual tiredness or weakness vomiting Rare Change in taste constipation cracks in the skin diarrhea itching lack or loss of strength loss of heat from the body loss of taste red, swollen skin scaly skin weight loss Drug Interactions DRUG INTERACTION Abametapir The serum concentration of Romidepsin can be increased when it is combined with Abametapir. Abatacept The metabolism of Romidepsin can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Romidepsin. Abrocitinib The serum concentration of Romidepsin can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Romidepsin can be decreased when combined with Acalabrutinib. Acenocoumarol Romidepsin may increase the anticoagulant activities of Acenocoumarol. Acetaminophen The metabolism of Romidepsin can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Romidepsin can be decreased when combined with Acetazolamide. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Romidepsin. Adalimumab The metabolism of Romidepsin can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Romidepsin. Afatinib The serum concentration of Romidepsin can be increased when it is combined with Afatinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Romidepsin. Albendazole The metabolism of Romidepsin can be decreased when combined with Albendazole. Aldesleukin The metabolism of Romidepsin can be decreased when combined with Aldesleukin. Alfentanil The metabolism of Romidepsin can be decreased when combined with Alfentanil. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Romidepsin. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Romidepsin. Alpelisib The metabolism of Romidepsin can be increased when combined with Alpelisib. Alprazolam The metabolism of Romidepsin can be decreased when combined with Alprazolam. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Romidepsin. Ambrisentan The serum concentration of Romidepsin can be increased when it is combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Romidepsin. Aminoglutethimide The metabolism of Romidepsin can be increased when combined with Aminoglutethimide. Amiodarone The metabolism of Romidepsin can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Romidepsin. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Romidepsin. Amobarbital The metabolism of Romidepsin can be increased when combined with Amobarbital. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Romidepsin. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Romidepsin. Amprenavir The metabolism of Romidepsin can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Romidepsin. Anakinra The metabolism of Romidepsin can be increased when combined with Anakinra. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Romidepsin. Antipyrine The metabolism of Romidepsin can be decreased when combined with Antipyrine. Apalutamide The serum concentration of Romidepsin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Romidepsin can be increased when it is combined with Apixaban. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Romidepsin. Apremilast The metabolism of Romidepsin can be increased when combined with Apremilast. Aprepitant The metabolism of Romidepsin can be decreased when combined with Aprepitant. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Romidepsin. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Romidepsin. Aripiprazole la The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Romidepsin. Armodafinil The metabolism of Romidepsin can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Romidepsin can be increased when it is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Articaine. Asciminib The serum concentration of Romidepsin can be increased when it is combined with Asciminib. Asenapine The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Asenapine. Astemizole The metabolism of Romidepsin can be decreased when combined with Astemizole. Asunaprevir The serum concentration of Romidepsin can be increased when it is combined with Asunaprevir. Ataluren The excretion of Romidepsin can be decreased when combined with Ataluren. Atazanavir The metabolism of Romidepsin can be decreased when combined with Atazanavir. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Romidepsin. Atorvastatin The metabolism of Romidepsin can be decreased when combined with Atorvastatin. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Romidepsin. Avacopan The metabolism of Romidepsin can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Romidepsin. Avatrombopag The serum concentration of Romidepsin can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Romidepsin. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Romidepsin. Azelastine The metabolism of Romidepsin can be decreased when combined with Azelastine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Romidepsin. Beclomethasone The metabolism of Romidepsin can be increased when combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Romidepsin. Belantamab mafod The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin. Belinostat The serum concentration of Romidepsin can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Romidepsin can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Romidepsin can be decreased when it is combined with Belzutifan. Bempedoic acid The excretion of Romidepsin can be decreased when combined with Bempedoic acid. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Romidepsin. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Romidepsin. Benzocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Benzocaine. Benzphetamine The metabolism of Romidepsin can be decreased when combined with Benzphetamine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Bepridil is combined with Romidepsin. Berotralstat The serum concentration of Romidepsin can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Romidepsin can be increased when combined with Betamethasone. Betamethasone The metabolism of Romidepsin can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Romidepsin can be increased when it is combined with Betrixaban. Bexarotene The metabolism of Romidepsin can be increased when combined with Bexarotene. Bicalutamide The metabolism of Romidepsin can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Romidepsin can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Romidepsin. Bimekizumab The metabolism of Romidepsin can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Romidepsin. Bisoprolol The serum concentration of Romidepsin can be increased when it is combined with Bisoprolol. Boceprevir The metabolism of Romidepsin can be decreased when combined with Boceprevir. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Romidepsin. Bosentan The metabolism of Romidepsin can be increased when combined with Bosentan. Bosutinib The metabolism of Romidepsin can be decreased when combined with Bosutinib. Brentuximab ved The metabolism of Romidepsin can be decreased when combined with Brentuximab vedotin. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Romidepsin. Brivaracetam The metabolism of Romidepsin can be decreased when combined with Brivaracetam. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Romidepsin. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Romidepsin. Budesonide The metabolism of Romidepsin can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Bupivacaine. Buprenorphine The metabolism of Romidepsin can be decreased when combined with Buprenorphine. Bupropion The metabolism of Romidepsin can be decreased when combined with Bupropion. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Romidepsin. Buspirone The metabolism of Romidepsin can be decreased when combined with Buspirone. Butacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Butacaine. Butalbital The metabolism of Romidepsin can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Romidepsin. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Romidepsin. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Romidepsin. Calcitriol The metabolism of Romidepsin can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Romidepsin can be increased when combined with Canakinumab. Candicidin The metabolism of Romidepsin can be decreased when combined with Candicidin. Cannabidiol The metabolism of Romidepsin can be decreased when combined with Cannabidiol. Capmatinib The serum concentration of Romidepsin can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Capsaicin. Carbamazepine The metabolism of Romidepsin can be increased when combined with Carbamazepine. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Romidepsin. Carfilzomib The serum concentration of Romidepsin can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Romidepsin can be increased when it is combined with Carvedilol. Cefradine The metabolism of Romidepsin can be increased when combined with Cefradine. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Romidepsin. Cenobamate The serum concentration of Romidepsin can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Romidepsin can be decreased when combined with Cephalexin. Ceritinib The metabolism of Romidepsin can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Romidepsin can be increased when combined with Cerivastatin. Certolizumab pe The metabolism of Romidepsin can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Romidepsin. Chloramphenicol The metabolism of Romidepsin can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Romidepsin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Romidepsin. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Romidepsin. Chlorpromazine The metabolism of Romidepsin can be increased when combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Romidepsin. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Romidepsin. Cimetidine The metabolism of Romidepsin can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Romidepsin. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Romidepsin. Ciprofloxacin The metabolism of Romidepsin can be decreased when combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Romidepsin. Cisplatin The metabolism of Romidepsin can be decreased when combined with Cisplatin. Citalopram The metabolism of Romidepsin can be decreased when combined with Citalopram. Clarithromycin The metabolism of Romidepsin can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Romidepsin. Clevidipine The metabolism of Romidepsin can be increased when combined with Clevidipine. Clindamycin The metabolism of Romidepsin can be decreased when combined with Clindamycin. Clobazam The metabolism of Romidepsin can be increased when combined with Clobazam. Clobetasol prop The metabolism of Romidepsin can be increased when combined with Clobetasol propionate. Clofazimine The serum concentration of Romidepsin can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Romidepsin can be increased when combined with Clofibrate. Clomifene The serum concentration of Romidepsin can be increased when it is combined with Clomifene. Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Romidepsin. Clonidine The metabolism of Clonidine can be decreased when combined with Romidepsin. Clopidogrel The metabolism of Romidepsin can be decreased when combined with Clopidogrel. Clotiazepam The metabolism of Romidepsin can be decreased when combined with Clotiazepam. Clozapine The metabolism of Romidepsin can be increased when combined with Clozapine. Cobicistat The metabolism of Romidepsin can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Romidepsin can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Cocaine. Colchicine The serum concentration of Romidepsin can be increased when it is combined with Colchicine. Conivaptan The metabolism of Romidepsin can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Romidepsin. Corticotropin The metabolism of Romidepsin can be increased when combined with Corticotropin. Cortisone ace The metabolism of Romidepsin can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Romidepsin can be decreased when combined with Crizotinib. Curcumin The metabolism of Romidepsin can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Romidepsin. Cyclophosphamide The metabolism of Romidepsin can be increased when combined with Cyclophosphamide. Cyclosporine The serum concentration of Romidepsin can be increased when it is combined with Cyclosporine. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Romidepsin. Cyproterone acetate The metabolism of Romidepsin can be decreased when combined with Cyproterone acetate. Dabigatran etexilate The serum concentration of Romidepsin can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Romidepsin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Romidepsin can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Romidepsin can be increased when it is combined with Dactinomycin. Dalfopristin The metabolism of Romidepsin can be decreased when combined with Dalfopristin. Danazol The metabolism of Romidepsin can be decreased when combined with Danazol. Dapsone The metabolism of Romidepsin can be decreased when combined with Dapsone. Daptomycin The serum concentration of Romidepsin can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Romidepsin. Darolutamide The serum concentration of Romidepsin can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Romidepsin can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Romidepsin can be increased when it is combined with Dasabuvir. Dasatinib The metabolism of Romidepsin can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Romidepsin can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Romidepsin can be increased when combined with Deferasirox. Deflazacort The metabolism of Romidepsin can be increased when combined with Deflazacort. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Romidepsin. Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Romidepsin. Delamanid Romidepsin may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Romidepsin can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Romidepsin. Desipramine The metabolism of Romidepsin can be decreased when combined with Desipramine. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Romidepsin. Desvenlafaxine The metabolism of Romidepsin can be decreased when combined with Desvenlafaxine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Deutetrabenazine. Dexamethasone The metabolism of Romidepsin can be increased when combined with Dexamethasone. Dexamethasone The serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone acetate. You Might Also Read Estrogen , Oestrogen; Types, Uses, Contra Indications, Side Effects, Interactions Dexbrompheniram The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Romidepsin. Dexchlorphenir The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Romidepsin. Dextromethorphan The metabolism of Romidepsin can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Romidepsin can be decreased when combined with Dextropropoxyphene. Diazepam The metabolism of Romidepsin can be decreased when combined with Diazepam. Diclofenac The metabolism of Romidepsin can be decreased when combined with Diclofenac. Dicloxacillin The metabolism of Romidepsin can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Romidepsin can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Romidepsin can be increased when combined with Difluocortolone. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Romidepsin. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Romidepsin. Dihydroergocornine The metabolism of Romidepsin can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Romidepsin can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Romidepsin can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Romidepsin can be decreased when combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Romidepsin. Dimethyl sulfoxide The metabolism of Romidepsin can be decreased when combined with Dimethyl sulfoxide. Diosmin The serum concentration of Romidepsin can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Diphenhydramine. Dipyridamole The excretion of Romidepsin can be decreased when combined with Dipyridamole. Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Romidepsin. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Romidepsin. Docetaxel The metabolism of Romidepsin can be decreased when combined with Docetaxel. Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Romidepsin. Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Romidepsin. Dolutegravir The serum concentration of Romidepsin can be increased when it is combined with Dolutegravir. Domperidone The risk or severity of QTc prolongation can be increased when Domperidone is combined with Romidepsin. Doravirine The metabolism of Doravirine can be decreased when combined with Romidepsin. Dosulepin The metabolism of Dosulepin can be decreased when combined with Romidepsin. Doxazosin The metabolism of Romidepsin can be decreased when combined with Doxazosin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Romidepsin. Doxorubicin The metabolism of Romidepsin can be decreased when combined with Doxorubicin. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Romidepsin. Dronabinol The metabolism of Romidepsin can be decreased when combined with Dronabinol. Dronedarone Romidepsin may increase the QTc-prolonging activities of Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Romidepsin. Drospirenone The metabolism of Romidepsin can be decreased when combined with Drospirenone. Dutasteride The metabolism of Romidepsin can be decreased when combined with Dutasteride. Duvelisib The metabolism of Romidepsin can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Dyclonine. Ebastine The metabolism of Romidepsin can be decreased when combined with Ebastine. Echinacea The metabolism of Romidepsin can be increased when combined with Echinacea. Edoxaban The serum concentration of Romidepsin can be increased when it is combined with Edoxaban. Efavirenz The metabolism of Romidepsin can be decreased when combined with Efavirenz. Elagolix The serum concentration of Romidepsin can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Romidepsin can be increased when it is combined with Elbasvir. Elexacaftor The metabolism of Romidepsin can be decreased when combined with Elexacaftor. Eliglustat The serum concentration of Romidepsin can be increased when it is combined with Eliglustat. Elvitegravir The metabolism of Romidepsin can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Romidepsin can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Romidepsin. Enasidenib The serum concentration of Romidepsin can be increased when it is combined with Enasidenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Romidepsin. Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin. Enfortumab vedotin The serum concentration of Romidepsin can be increased when it is combined with Enfortumab vedotin. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Romidepsin. Entrectinib The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Entrectinib. Enzalutamide The serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Romidepsin. Epinephrine The metabolism of Romidepsin can be decreased when combined with Epinephrine. Eplerenone The metabolism of Romidepsin can be decreased when combined with Eplerenone. Erdafitinib The serum concentration of Romidepsin can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Romidepsin can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Romidepsin. Erlotinib The metabolism of Romidepsin can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Romidepsin can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Romidepsin can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Romidepsin. Escitalopram The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Romidepsin. Esketamine The metabolism of Romidepsin can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Romidepsin can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Romidepsin can be increased when combined with Eslicarbazepine acetate. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Romidepsin. Estetrol The metabolism of Romidepsin can be decreased when combined with Estetrol. Estradiol The metabolism of Romidepsin can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Romidepsin can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Romidepsin can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Romidepsin can be increased when combined with Estradiol cypionate. Estradiol dienanth The metabolism of Romidepsin can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Romidepsin can be increased when combined with Estradiol valerate. Etanercept The metabolism of Romidepsin can be increased when combined with Etanercept. Ethambutol The metabolism of Romidepsin can be decreased when combined with Ethambutol. Ethanol The metabolism of Romidepsin can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Romidepsin can be decreased when combined with Ethinylestradiol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Romidepsin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Romidepsin. Etoricoxib The metabolism of Romidepsin can be decreased when combined with Etoricoxib. Etravirine The metabolism of Romidepsin can be increased when combined with Etravirine. Everolimus The serum concentration of Romidepsin can be increased when it is combined with Everolimus. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Romidepsin. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Romidepsin. Favipiravir The serum concentration of Romidepsin can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Romidepsin can be increased when it is combined with Fedratinib. Felbamate The metabolism of Romidepsin can be increased when combined with Felbamate. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Romidepsin. Fenfluramine The metabolism of Romidepsin can be decreased when combined with Fenfluramine. Fenofibrate The metabolism of Romidepsin can be decreased when combined with Fenofibrate. Fexinidazole The risk or severity of adverse effects can be increased when Romidepsin is combined with Fexinidazole. Fexofenadine The serum concentration of Romidepsin can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Romidepsin can be increased when it is combined with Filgotinib. Finasteride The metabolism of Romidepsin can be decreased when combined with Finasteride. Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Romidepsin. Flibanserin The serum concentration of Romidepsin can be increased when it is combined with Flibanserin. Flucloxacillin The metabolism of Romidepsin can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Romidepsin can be increased when it is combined with Fluconazole. Flunisolide The metabolism of Romidepsin can be increased when combined with Flunisolide. Flunitrazepam The metabolism of Romidepsin can be decreased when combined with Flunitrazepam. Fluocinolone ace The metabolism of Romidepsin can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Romidepsin can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Romidepsin can be increased when combined with Fluocortolone. Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Romidepsin. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Romidepsin. Flupentixol The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Romidepsin. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Romidepsin. Flutamide The metabolism of Romidepsin can be decreased when combined with Flutamide. Fluticasone The metabolism of Romidepsin can be increased when combined with Fluticasone. Fluticasone fu The metabolism of Fluticasone furoate can be decreased when combined with Romidepsin. Fluticasone pr The metabolism of Romidepsin can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Romidepsin can be increased when combined with Fluvastatin. Fluvoxamine The metabolism of Romidepsin can be decreased when combined with Fluvoxamine. Formestane The metabolism of Romidepsin can be increased when combined with Formestane. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Romidepsin. Fosamprenavir The metabolism of Romidepsin can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Romidepsin can be increased when combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Romidepsin. Fosnetupitant The metabolism of Romidepsin can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Romidepsin can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Romidepsin can be decreased when combined with Fostamatinib. Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Romidepsin. Fusidic acid The metabolism of Romidepsin can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Romidepsin can be increased when it is combined with Futibatinib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Romidepsin. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Romidepsin. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Romidepsin. Gefitinib The metabolism of Romidepsin can be decreased when combined with Gefitinib. Gemcitabine The serum concentration of Romidepsin can be increased when it is combined with Gemcitabine. Gemfibrozil The excretion of Romidepsin can be decreased when combined with Gemfibrozil. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Romidepsin. Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Romidepsin. Ginkgo biloba The metabolism of Romidepsin can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Romidepsin can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Romidepsin can be increased when it is combined with Glecaprevir. Glyburide The metabolism of Romidepsin can be decreased when combined with Glyburide. Glycerol phenylbu The metabolism of Romidepsin can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Romidepsin can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Romidepsin. Grazoprevir The serum concentration of Romidepsin can be increased when it is combined with Grazoprevir. Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Romidepsin. Griseofulvin The metabolism of Romidepsin can be increased when combined with Griseofulvin. Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Romidepsin. Haloperidol The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Haloperidol. Halothane The metabolism of Romidepsin can be decreased when combined with Halothane. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Romidepsin. Hydralazine The metabolism of Romidepsin can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Romidepsin. Hydrocodone The metabolism of Romidepsin can be decreased when combined with Hydrocodone. Hydrocortamate The metabolism of Romidepsin can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Romidepsin can be increased when combined with Hydrocortisone. Hydrocortisone a The metabolism of Romidepsin can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyr The metabolism of Romidepsin can be increased when combined with Hydrocortisone butyrate. Hydrocortisone c The metabolism of Hydrocortisone cypionate can be decreased when combined with Romidepsin. Hydrocortisone phos The metabolism of Hydrocortisone phosphate can be decreased when combined with Romidepsin. Hydrocortisone succi The metabolism of Romidepsin can be increased when combined with Hydrocortisone succinate. Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Romidepsin. Hydroxyprogesterone The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Romidepsin. Hydroxyzine The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Romidepsin. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Romidepsin. Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Romidepsin. Idelalisib The metabolism of Romidepsin can be decreased when combined with Idelalisib. Ifosfamide The metabolism of Romidepsin can be increased when combined with Ifosfamide. Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Romidepsin. Imatinib The serum concentration of Romidepsin can be increased when it is combined with Imatinib. Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Romidepsin. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Romidepsin. Indinavir The metabolism of Romidepsin can be decreased when combined with Indinavir. Infigratinib The metabolism of Romidepsin can be decreased when combined with Infigratinib. Infliximab The metabolism of Romidepsin can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Romidepsin. Inotuzumab ozog The serum concentration of Romidepsin can be increased when it is combined with Inotuzumab ozogamicin. Irbesartan The metabolism of Romidepsin can be decreased when combined with Irbesartan. Irinotecan The metabolism of Romidepsin can be decreased when combined with Irinotecan. Isavuconazole The serum concentration of Romidepsin can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Romidepsin can be increased when it is combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Romidepsin. Isoniazid The metabolism of Romidepsin can be decreased when combined with Isoniazid. Isradipine The metabolism of Romidepsin can be decreased when combined with Isradipine. Istradefylline The serum concentration of Romidepsin can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Romidepsin can be decreased when combined with Itraconazole. Ivabradine The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivabradine. Ivacaftor The serum concentration of Romidepsin can be increased when it is combined with Ivacaftor. Ivermectin The excretion of Romidepsin can be decreased when combined with Ivermectin. Ivosidenib The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivosidenib. Ixabepilone The serum concentration of Romidepsin can be increased when it is combined with Ixabepilone. Ketamine The metabolism of Romidepsin can be decreased when combined with Ketamine. You Might Also Read Minoxidil Oral - Uses, Dosage, Side Effects, Interactions Ketazolam The metabolism of Romidepsin can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Romidepsin can be decreased when combined with Ketoconazole. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Romidepsin. Lacosamide The metabolism of Romidepsin can be decreased when combined with Lacosamide. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Romidepsin. Lanreotide The metabolism of Romidepsin can be decreased when combined with Lanreotide. Lapatinib The serum concentration of Romidepsin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Romidepsin can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Romidepsin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Romidepsin can be increased when it is combined with Ledipasvir. Lefamulin Lefamulin may increase the QTc-prolonging activities of Romidepsin. Lemborexant The serum concentration of Romidepsin can be decreased when it is combined with Lemborexant. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Romidepsin. Lercanidipine The metabolism of Romidepsin can be decreased when combined with Lercanidipine. Lesinurad The metabolism of Romidepsin can be increased when combined with Lesinurad. Letermovir The metabolism of Romidepsin can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin. Levacetylme The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Romidepsin. Levamlodipine The metabolism of Levamlodipine can be decreased when combined with Romidepsin. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Romidepsin. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Romidepsin. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Romidepsin. Levoketoconazole The metabolism of Romidepsin can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Romidepsin. Levonorgestrel The metabolism of Romidepsin can be decreased when combined with Levonorgestrel. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Romidepsin. Levothyroxine The serum concentration of Romidepsin can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Romidepsin. Linagliptin The serum concentration of Romidepsin can be increased when it is combined with Linagliptin. Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Romidepsin. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Romidepsin. Lomitapide The serum concentration of Romidepsin can be increased when it is combined with Lomitapide. Lonafarnib The metabolism of Romidepsin can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Romidepsin can be increased when it is combined with Loncastuximab tesirine. Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Romidepsin. Lopinavir The metabolism of Romidepsin can be decreased when combined with Lopinavir. Lorcaserin The metabolism of Romidepsin can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Romidepsin can be decreased when it is combined with Lorlatinib. Losartan The metabolism of Romidepsin can be decreased when combined with Losartan. Lovastatin The metabolism of Romidepsin can be decreased when combined with Lovastatin. Loxapine The serum concentration of Romidepsin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Romidepsin can be decreased when it is combined with Lumacaftor. Lumefantrine The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Romidepsin. Lusutrombopag The serum concentration of Romidepsin can be increased when it is combined with Lusutrombopag. Macimorelin The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Macimorelin. Manidipine The metabolism of Romidepsin can be decreased when combined with Manidipine. Mannitol The serum concentration of Romidepsin can be increased when it is combined with Mannitol. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Romidepsin. Maribavir The serum concentration of Romidepsin can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Romidepsin can be decreased when it is combined with Mavacamten. Medroxyproge The metabolism of Romidepsin can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Romidepsin can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Meloxicam. Memantine The metabolism of Romidepsin can be decreased when combined with Memantine. Meperidine The metabolism of Romidepsin can be decreased when combined with Meperidine. Mephenytoin The metabolism of Romidepsin can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Mepivacaine. Meprednisone The metabolism of Romidepsin can be increased when combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Romidepsin. Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Romidepsin. Methadone The metabolism of Romidepsin can be decreased when combined with Methadone. Methimazole The metabolism of Romidepsin can be decreased when combined with Methimazole. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Romidepsin. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Romidepsin. Methoxyflurane The metabolism of Romidepsin can be decreased when combined with Methoxyflurane. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Romidepsin. Methylene blue The serum concentration of Romidepsin can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Romidepsin can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Romidepsin can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Romidepsin can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Romidepsin can be decreased when combined with Methylprednisone. Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Romidepsin. Methysergide The metabolism of Romidepsin can be decreased when combined with Methysergide. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Romidepsin. Metreleptin The metabolism of Romidepsin can be increased when combined with Metreleptin. Metronidazole The metabolism of Romidepsin can be decreased when combined with Metronidazole. Metyrapone The metabolism of Romidepsin can be increased when combined with Metyrapone. Mexiletine The metabolism of Romidepsin can be decreased when combined with Mexiletine. Mianserin The metabolism of Romidepsin can be decreased when combined with Mianserin. Miconazole The metabolism of Romidepsin can be decreased when combined with Miconazole. Midazolam The metabolism of Romidepsin can be decreased when combined with Midazolam. Midostaurin The metabolism of Romidepsin can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Romidepsin can be decreased when it is combined with Mifepristone. Milnacipran The metabolism of Romidepsin can be decreased when combined with Milnacipran. Miocamycin The metabolism of Romidepsin can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Romidepsin can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Romidepsin can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Romidepsin can be increased when combined with Mitapivat. Mitotane The metabolism of Romidepsin can be increased when combined with Mitotane. Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Romidepsin. Mobocertinib The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Mobocertinib. Modafinil The metabolism of Romidepsin can be increased when combined with Modafinil. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Romidepsin. Mometasone furoate The metabolism of Romidepsin can be increased when combined with Mometasone furoate. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Romidepsin. Morphine The serum concentration of Romidepsin can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Romidepsin can be decreased when combined with Mosunetuzumab. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin. Mycophenolate The metabolism of Romidepsin can be decreased when combined with Mycophenolate mofetil. Nafcillin The metabolism of Romidepsin can be increased when combined with Nafcillin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Romidepsin. Nateglinide The metabolism of Romidepsin can be decreased when combined with Nateglinide. Nefazodone The metabolism of Romidepsin can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Romidepsin can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Romidepsin can be increased when it is combined with Neratinib. Netupitant The serum concentration of Romidepsin can be increased when it is combined with Netupitant. Nevirapine The metabolism of Romidepsin can be increased when combined with Nevirapine. Niacin The metabolism of Romidepsin can be decreased when combined with Niacin. Nicardipine The metabolism of Romidepsin can be decreased when combined with Nicardipine. Nicotine The metabolism of Romidepsin can be decreased when combined with Nicotine. Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Romidepsin. Nilotinib The metabolism of Romidepsin can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Romidepsin can be decreased when combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Romidepsin. Nintedanib The metabolism of Romidepsin can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Romidepsin can be decreased when combined with Nisoldipine. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Romidepsin. Norethisterone The metabolism of Romidepsin can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Romidepsin. Norgestimate The serum concentration of Romidepsin can be increased when it is combined with Norgestimate. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Romidepsin. Noscapine The metabolism of Romidepsin can be decreased when combined with Noscapine. Novobiocin The excretion of Romidepsin can be decreased when combined with Novobiocin. Nystatin The excretion of Romidepsin can be decreased when combined with Nystatin. Octreotide The serum concentration of Romidepsin can be increased when it is combined with Octreotide. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Romidepsin. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Romidepsin. Olaparib The metabolism of Romidepsin can be decreased when combined with Olaparib. Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Romidepsin. Omadacycline The serum concentration of Romidepsin can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Romidepsin can be increased when it is combined with Ombitasvir. Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Romidepsin. Oritavancin The metabolism of Romidepsin can be increased when combined with Oritavancin. Orphenadrine The metabolism of Romidepsin can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Romidepsin can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Romidepsin can be decreased when combined with Osimertinib. Ospemifene The metabolism of Romidepsin can be decreased when combined with Ospemifene. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin. Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Romidepsin. Oxcarbazepine The metabolism of Romidepsin can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Oxybuprocaine. Oxybutynin The metabolism of Romidepsin can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Romidepsin can be decreased when combined with Oxycodone. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin. Paclitaxel The metabolism of Romidepsin can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Romidepsin can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Romidepsin can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Romidepsin can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Romidepsin. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin. Paritaprevir The serum concentration of Romidepsin can be increased when it is combined with Paritaprevir. Paroxetine The metabolism of Romidepsin can be decreased when combined with Paroxetine. Pasireotide The metabolism of Romidepsin can be decreased when combined with Pasireotide. Pazopanib The metabolism of Romidepsin can be decreased when combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Romidepsin. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Romidepsin. Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Romidepsin. Pentobarbital The metabolism of Romidepsin can be increased when combined with Pentobarbital. Perampanel The metabolism of Romidepsin can be increased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Romidepsin. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Romidepsin. Pexidartinib The excretion of Romidepsin can be decreased when combined with Pexidartinib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Romidepsin. Phenobarbital The metabolism of Romidepsin can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Phenol. Phenylbutazone The metabolism of Romidepsin can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Romidepsin can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Romidepsin can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Romidepsin can be decreased when combined with Pimavanserin. Pimozide The metabolism of Pimozide can be decreased when combined with Romidepsin. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Romidepsin. Piperaquine The metabolism of Romidepsin can be decreased when combined with Piperaquine. Pitolisant The serum concentration of Romidepsin can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Romidepsin. Ponatinib The serum concentration of Romidepsin can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Romidepsin. Posaconazole The metabolism of Romidepsin can be decreased when combined with Posaconazole. Pralsetinib The serum concentration of Romidepsin can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Pramocaine. Prasugrel The metabolism of Prasugrel can be decreased when combined with Romidepsin. Pravastatin The serum concentration of Romidepsin can be increased when it is combined with Pravastatin. Praziquantel The metabolism of Romidepsin can be decreased when combined with Praziquantel. Prednisolone The metabolism of Romidepsin can be increased when combined with Prednisolone. Prednisolone The metabolism of Romidepsin can be increased when combined with Prednisolone acetate. Prednisolone phos The serum concentration of Romidepsin can be decreased when it is combined with Prednisolone phosphate. Prednisone acetate The metabolism of Romidepsin can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Romidepsin. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Romidepsin. Pretomanid The serum concentration of Romidepsin can be increased when it is combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Prilocaine. Primaquine The metabolism of Romidepsin can be decreased when combined with Primaquine. Primidone The metabolism of Romidepsin can be increased when combined with Primidone. Probenecid The metabolism of Romidepsin can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Romidepsin. Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Romidepsin. Procaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Romidepsin. Progesterone The metabolism of Romidepsin can be decreased when combined with Progesterone. Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Romidepsin. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Romidepsin. Propafenone The serum concentration of Romidepsin can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Proparacaine. Propofol The metabolism of Romidepsin can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Propoxycaine. Propranolol The metabolism of Romidepsin can be decreased when combined with Propranolol. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Romidepsin. Quazepam The metabolism of Romidepsin can be decreased when combined with Quazepam. Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Romidepsin. Quinidine The serum concentration of Romidepsin can be increased when it is combined with Quinidine. Quinine The serum concentration of Romidepsin can be increased when it is combined with Quinine. Quinupristin The metabolism of Romidepsin can be decreased when combined with Quinupristin. Raloxifene The metabolism of Romidepsin can be decreased when combined with Raloxifene. Ranolazine The serum concentration of Romidepsin can be increased when it is combined with Ranolazine. Regorafenib The serum concentration of Romidepsin can be increased when it is combined with Regorafenib. Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Romidepsin. Remdesivir The metabolism of Romidepsin can be decreased when combined with Remdesivir. Reserpine The serum concentration of Romidepsin can be increased when it is combined with Reserpine. Revefenacin The serum concentration of Romidepsin can be increased when it is combined with Revefenacin. Ribociclib The metabolism of Romidepsin can be decreased when combined with Ribociclib. Rifabutin The metabolism of Romidepsin can be increased when combined with Rifabutin. Rifampicin The serum concentration of Romidepsin can be increased when it is combined with Rifampicin. Rifamycin The serum concentration of Romidepsin can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Romidepsin can be increased when combined with Rifapentine. Rilonacept The metabolism of Romidepsin can be increased when combined with Rilonacept. Rilpivirine The metabolism of Romidepsin can be decreased when combined with Rilpivirine. Rimegepant The serum concentration of Romidepsin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Romidepsin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Romidepsin can be increased when it is combined with Ripretinib. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Romidepsin. Ritonavir The serum concentration of Romidepsin can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Romidepsin can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Romidepsin can be increased when combined with Rofecoxib. Roflumilast The metabolism of Romidepsin can be decreased when combined with Roflumilast. Rolapitant The serum concentration of Romidepsin can be increased when it is combined with Rolapitant. Ropivacaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Romidepsin. Rosuvastatin The metabolism of Romidepsin can be decreased when combined with Rosuvastatin. Roxithromycin The metabolism of Romidepsin can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Romidepsin can be decreased when combined with Rucaparib. Rufinamide The metabolism of Romidepsin can be increased when combined with Rufinamide. Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Romidepsin. Sacubitril The excretion of Romidepsin can be decreased when combined with Sacubitril. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Romidepsin. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Romidepsin. Sapropterin The serum concentration of Romidepsin can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Romidepsin can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Romidepsin can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Romidepsin can be increased when combined with Sarilumab. Satralizumab The serum concentration of Romidepsin can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Saxagliptin can be decreased when combined with Romidepsin. Secobarbital The metabolism of Romidepsin can be increased when combined with Secobarbital. Secukinumab The metabolism of Romidepsin can be increased when combined with Secukinumab. Selegiline The metabolism of Romidepsin can be decreased when combined with Selegiline. Selexipag The serum concentration of Romidepsin can be increased when it is combined with Selexipag. Selinexor The excretion of Romidepsin can be decreased when combined with Selinexor. Selumetinib The serum concentration of Romidepsin can be increased when it is combined with Selumetinib. Sertraline The metabolism of Romidepsin can be decreased when combined with Sertraline. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Romidepsin. Sildenafil The serum concentration of Romidepsin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Romidepsin can be increased when it is combined with Silodosin. Siltuximab The metabolism of Romidepsin can be increased when combined with Siltuximab. Simeprevir The serum concentration of Romidepsin can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Romidepsin can be increased when it is combined with Simvastatin. Siponimod The metabolism of Romidepsin can be decreased when combined with Siponimod. Sirolimus The metabolism of Sirolimus can be decreased when combined with Romidepsin. Sitagliptin The serum concentration of Romidepsin can be increased when it is combined with Sitagliptin. Sitaxentan The metabolism of Romidepsin can be decreased when combined with Sitaxentan. Sofosbuvir The serum concentration of Romidepsin can be increased when it is combined with Sofosbuvir. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Romidepsin. Somatostatin The metabolism of Romidepsin can be decreased when combined with Somatostatin. Somatrogon The metabolism of Romidepsin can be increased when combined with Somatrogon. Sorafenib The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Sorafenib. Sotagliflozin The serum concentration of Romidepsin can be increased when it is combined with Sotagliflozin. Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Romidepsin. Sotorasib The serum concentration of Romidepsin can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Romidepsin. St. John’s Wort The serum concentration of Romidepsin can be decreased when it is combined with St. John’s Wort. Stiripentol The metabolism of Romidepsin can be decreased when combined with Stiripentol. Sulfamethoxazole The metabolism of Romidepsin can be decreased when combined with Sulfamethoxazole. Sulfaphenazole The metabolism of Romidepsin can be decreased when combined with Sulfaphenazole. Sulfasalazine The excretion of Romidepsin can be decreased when combined with Sulfasalazine. Sulfinpyrazone The metabolism of Romidepsin can be increased when combined with Sulfinpyrazone. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Romidepsin. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Romidepsin. Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Romidepsin. Sunitinib The metabolism of Sunitinib can be decreased when combined with Romidepsin. Suvorexant The serum concentration of Romidepsin can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Romidepsin can be increased when it is combined with Tacrolimus. Tadalafil The metabolism of Romidepsin can be decreased when combined with Tadalafil. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Romidepsin. Tamoxifen The serum concentration of Romidepsin can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Romidepsin can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Romidepsin can be decreased when combined with Tazemetostat. Technetium The serum concentration of Romidepsin can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Romidepsin can be increased when combined with Tecovirimat. Tegafur The metabolism of Tegafur can be decreased when combined with Romidepsin. You Might Also Read Azelaic Acid Gel - Uses, Dosage, Side Effects, Interaction Tegaserod The serum concentration of Romidepsin can be increased when it is combined with Tegaserod. Telaprevir The metabolism of Romidepsin can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Romidepsin. Telithromycin The metabolism of Romidepsin can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Romidepsin can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Romidepsin can be increased when it is combined with Temsirolimus. Teniposide The metabolism of Romidepsin can be decreased when combined with Teniposide. Tenofovir alafen The metabolism of Romidepsin can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Romidepsin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Romidepsin can be increased when it is combined with Tepotinib. Terbinafine The metabolism of Romidepsin can be increased when combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Romidepsin. Terfenadine The metabolism of Romidepsin can be decreased when combined with Terfenadine. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Romidepsin. Testosterone The metabolism of Romidepsin can be increased when combined with Testosterone. Testosterone The metabolism of Testosterone cypionate can be decreased when combined with Romidepsin. Testosterone The metabolism of Testosterone enanthate can be decreased when combined with Romidepsin. Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Romidepsin. Tetracaine The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Tetracaine. Tetracycline The metabolism of Romidepsin can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Romidepsin can be increased when it is combined with Tezacaftor. Thalidomide The metabolism of Romidepsin can be increased when combined with Thalidomide. Thiamylal The metabolism of Romidepsin can be increased when combined with Thiamylal. Thioridazine The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Romidepsin. Thiosulfuric acid The metabolism of Romidepsin can be increased when combined with Thiosulfuric acid. Thiotepa The metabolism of Romidepsin can be decreased when combined with Thiotepa. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Romidepsin. Ticagrelor The serum concentration of Romidepsin can be increased when it is combined with Ticagrelor. Ticlopidine The metabolism of Romidepsin can be decreased when combined with Ticlopidine. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Romidepsin. Tipranavir The metabolism of Romidepsin can be decreased when combined with Tipranavir. Tivozanib The serum concentration of Romidepsin can be increased when it is combined with Tivozanib. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Romidepsin. Tocilizumab The metabolism of Romidepsin can be increased when combined with Tocilizumab. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Romidepsin. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Romidepsin. Topiramate The metabolism of Romidepsin can be increased when combined with Topiramate. Topotecan The serum concentration of Topotecan can be increased when it is combined with Romidepsin. Toremifene The serum concentration of Romidepsin can be increased when it is combined with Toremifene. Tramadol The metabolism of Romidepsin can be decreased when combined with Tramadol. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Romidepsin. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Romidepsin. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Romidepsin. Tretinoin The metabolism of Romidepsin can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Romidepsin can be increased when combined with Triamcinolone. Triazolam The metabolism of Romidepsin can be decreased when combined with Triazolam. Triclabendazole The metabolism of Romidepsin can be decreased when combined with Triclabendazole. Trilaciclib The serum concentration of Romidepsin can be increased when it is combined with Trilaciclib. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Romidepsin. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Romidepsin. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Romidepsin. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Romidepsin. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Romidepsin. Troglitazone The metabolism of Romidepsin can be increased when combined with Troglitazone. Troleandomycin The metabolism of Romidepsin can be decreased when combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Romidepsin. Tucatinib Tucatinib may decrease the excretion rate of Romidepsin which could result in a higher serum level. Ubrogepant The serum concentration of Romidepsin can be increased when it is combined with Ubrogepant. Udenafil The metabolism of Udenafil can be decreased when combined with Romidepsin. Umbralisib The serum concentration of Romidepsin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Romidepsin can be increased when it is combined with Umeclidinium. Valbenazine The metabolism of Valbenazine can be decreased when combined with Romidepsin. Valproic acid The metabolism of Romidepsin can be decreased when combined with Valproic acid. Vandetanib The serum concentration of Romidepsin can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Romidepsin can be increased when it is combined with Vardenafil. Velpatasvir The serum concentration of Romidepsin can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Romidepsin can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Romidepsin can be increased when it is combined with Venetoclax. Verapamil The serum concentration of Romidepsin can be increased when it is combined with Verapamil. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Romidepsin. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Romidepsin. Viloxazine The metabolism of Romidepsin can be decreased when combined with Viloxazine. Vinblastine The metabolism of Romidepsin can be increased when combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Romidepsin. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Romidepsin. Vitamin E The metabolism of Romidepsin can be increased when combined with Vitamin E. Voclosporin The serum concentration of Romidepsin can be increased when it is combined with Voclosporin. Vonoprazan The metabolism of Vonoprazan can be decreased when combined with Romidepsin. Vorapaxar The serum concentration of Romidepsin can be increased when it is combined with Vorapaxar. Voriconazole The metabolism of Romidepsin can be decreased when combined with Voriconazole. Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Romidepsin is combined with Vorinostat. Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Romidepsin. Voxelotor The serum concentration of Romidepsin can be increased when it is combined with Voxelotor. Voxilaprevir The serum concentration of Romidepsin can be increased when it is combined with Voxilaprevir. Warfarin Romidepsin may increase the anticoagulant activities of Warfarin. Zafirlukast The metabolism of Romidepsin can be decreased when combined with Zafirlukast. Zaleplon The metabolism of Romidepsin can be decreased when combined with Zaleplon. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Romidepsin. Zimelidine The metabolism of Romidepsin can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ziprasidone. Zonisamide The serum concentration of Romidepsin can be increased when it is combined with Zonisamide. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Romidepsin. Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Pregnancy Based on its mechanism of action and findings from animal studies, Romidepsin Injection can cause embryofetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on romidepsin use in pregnant women to inform a drug associated risk of major birth defects and miscarriage. In an animal reproductive study, romidepsin was embryocidal and caused adverse developmental outcomes including embryo-fetal toxicity and malformations at exposures below those in patients at the recommended dose (see Data). Advise pregnant women of the potential risk to a fetus and to avoid becoming pregnant while receiving romidepsin and for at least 1 month after the last dose. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of romidepsin or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the breastfed child, advise lactating women not to breastfeed during treatment with Romidepsin Injection and for at least 1 week after the last dose. Why is this medication prescribed? Romidepsin injection is used to treat cutaneous T-cell lymphoma (CTCL; a group of cancers of the immune system that first appear as skin rashes) in people who have already been treated with at least one other medication. Romidepsin injection is also used to treat peripheral T-cell lymphoma (PTCL; a type of non-Hodgkin’s lymphoma) in people who have already been treated with at least one other medication. Romidepsin injection is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by slowing the growth of cancer cells. How should this medicine be used? Romidepsin injection comes as a powder to be mixed with liquid to be injected intravenously (into a vein) over a 4-hour period by a doctor or nurse. It is usually given on days 1, 8, and 15 of a 28-day cycle. This cycle may be repeated as long as the medication continues to work and does not cause severe side effects. Talk to your doctor about any side effects you experience during your treatment with romidepsin injection. If you experience certain severe side effects, your doctor may stop your treatment permanently or temporarily and/or may decrease your dose. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving romidepsin injection, tell your doctor and pharmacist if you are allergic to romidepsin injection, any other medications, or any of the ingredients in romidepsin injection. Ask your pharmacist or check the patient information for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antibiotics such as clarithromycin (Biaxin), erythromycin (E.E.S., E-Mycin, Erythrocin), moxifloxacin (Avelox), and telithromycin (Ketek); anticoagulants (blood thinners) such as warfarin (Coumadin, Jantoven); antifungals such as itraconazole (Sporanox), ketoconazole (Nizoral), and voriconazole (Vfend); cisapride (Propulsid) (not available in the U.S.); dexamethasone; medications for human immunodeficiency virus (HIV) such as atazanavir (Reyataz), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (in Kaletra, Norvir), and saquinavir (Invirase); medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), dofetilide (Tikosyn), procainamide (Procanbid, Pronestyl), quinidine (Quinidex), and sotalol (Betapace, Betapace AF); certain medications for seizures such as carbamazepine (Epitol, Equetro, Tegretol), phenobarbital, and phenytoin (Dilantin); nefazodone; pimozide (Orap); rifabutin (Mycobutin); rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); rifapentine (Priftin); sparfloxacin (Zagam); or thioridazine (Mellaril). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with romidepsin injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor what herbal products you are taking, especially St. John’s wort. tell your doctor if you have nausea, vomiting, or diarrhea before you begin your treatment with romidepsin injection. Also tell your doctor if you have or have ever had a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), an irregular or fast heartbeat, too much or too little potassium or magnesium in your blood, hepatitis B (HBV; a virus that infects the liver and may cause severe liver damage or liver cancer), Epstein Barr virus (EBV; a herpes virus that causes infectious mononucleosis and is associated with certain cancers), or liver, kidney, or heart disease. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Your doctor may check to see if you are pregnant before you begin your treatment. You should use birth control to prevent pregnancy during your treatment with romidepsin injection and for at least one month after your final dose. However, you should not use hormonal (estrogen) contraceptives (birth control pills, patches, rings, implants, or injections) because romidepsin injection may stop these medications from working as they should. If you are a male with a female partner who could become pregnant, be sure to use birth control during your treatment with romidepsin injection and for at least one month after your final dose. Talk to your doctor about birth control methods that you can use. If you become pregnant while receiving romidepsin injection, call your doctor. Romidepsin injection may harm the fetus. You should not breastfeed during your treatment with romidepsin injection and for at least 1 week after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving romidepsin injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208574Orig2lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022393s017lbl.pdf https://www.cancer.gov/about-cancer/treatment/drugs/romidepsin https://pubchem.ncbi.nlm.nih.gov/compound/Romidepsin https://go.drugbank.com/drugs/DB06176 https://www.drugs.com/mtm/romidepsin.html https://www.mayoclinic.org/drugs-supplements/romidepsin-intravenous-route/side-effects/drg-20073451 https://en.wikipedia.org/wiki/Romidepsin https://medlineplus.gov/druginfo/meds/a610005.html https://www.webmd.com/drugs/2/drug-153830/romidepsin-intravenous/details/list-contraindications https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ https://www.nlm.nih.gov/copyright.html https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ROMIDEPSIN https://www.hiv.gov/about-us/mission-and-team https://clinicalinfo.hiv.gov//en/drugs/romidepsin/patient https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/books/n/livertox/Romidepsin/ EPA DSSTox https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources https://comptox.epa.gov/dashboard/DTXSID8048579 https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/216945 EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice https://www.ema.europa.eu/en/medicines/human/EPAR/istodax https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001023-pip01-10 FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ Human Metabolome Database (HMDB) http://www.hmdb.ca/citing http://www.hmdb.ca/metabolites/HMDB0250632 National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs https://www.cancer.gov/policies/copyright-reuse https://www.cancer.gov/about-cancer/treatment/drugs/romidepsin NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/877510 https://pubchem.ncbi.nlm.nih.gov Wikidata https://creativecommons.org/publicdomain/zero/1.0/ https://www.wikidata.org/wiki/Q104193374 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/mesh/67087123 http://www.nlm.nih.gov/mesh/meshhome.html https://www.ncbi.nlm.nih.gov/mesh/68000903 https://www.ncbi.nlm.nih.gov/mesh/68056572 UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html https://www.ncbi.nlm.nih.gov/projects/linkout References